Myriad Genetics (MYGN) Consolidated Net Income (2009 - 2026)

Myriad Genetics has disclosed Consolidated Net Income across 18 years of filings, most recently posting -$34.1 million for Q1 2026.

• In Q1 2026, Consolidated Net Income fell 34000.0% year-over-year to -$34.1 million; the TTM figure through Mar 2026 stood at -$399.9 million (down 294.38% YoY), while the FY2025 annual figure was -$365.9 million, down 187.43% from the prior year.
• Consolidated Net Income fell to -$34.1 million in Q1 2026, from -$7.9 million in the prior quarter.
• Over the last five years, Consolidated Net Income for MYGN reached as high as -$100000.0 in Q1 2025 and fell as low as -$330.5 million in Q2 2025.
• The 5-year median for Consolidated Net Income is -$34.1 million (2026), against an average of -$53.1 million.
• Annual changes were most pronounced in 2025 — Consolidated Net Income surged 99.62% — and 2026, when it slumped 34000.0%.
• A 5-year view of Consolidated Net Income shows it stood at -$42.3 million in 2022, then rose by 26.24% to -$31.2 million in 2023, then sank by 36.22% to -$42.5 million in 2024, then soared by 81.41% to -$7.9 million in 2025, then tumbled by 331.65% to -$34.1 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$34.1 million, -$7.9 million, and -$27.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.